hPLA2G7-R92H Mouse
Product Name
hPLA2G7-R92H Mouse
Product ID
C001940
Strain Name
C57BL/6NCya-Pla2g7em1(hPLA2G7*R92H)/Cya
Backgroud
C57BL/6NCya
Status
When using this mouse strain in a publication, please cite “hPLA2G7-R92H Mouse (Catalog C001940) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Gene Name
PLA2G7
Gene Alias
PAFAD, PAFAH, LP-PLA2, LDL-PLA2
NCBI ID
Chromosome
Chr 6 (Human)
MGI ID
Datasheet
Strain Description
The PLA2G7 gene encodes a secreted enzyme known as lipoprotein-associated phospholipase A2 (Lp-PLA2) or platelet-activating factor acetylhydrolase (PAF-AH). This enzyme functions as a calcium-independent phospholipase that primarily catalyzes the degradation of platelet-activating factor (PAF) into inactive products and hydrolyzes oxidatively truncated phospholipids, thereby regulating inflammatory and oxidative stress responses [1]. Though it is expressed at low levels across many tissues, the gene is significantly enriched in lymphoid tissues and the placenta, and it is notably produced by inflammatory cells such as macrophages, monocytes, and mast cells. Within the circulatory system, the protein primarily associates with low-density lipoprotein (LDL) particles, where its activity is a well-recognized biomarker for atherosclerosis and coronary artery disease [2]. Beyond cardiovascular conditions, dysregulation or genetic defects in PLA2G7 are associated with PAF acetylhydrolase deficiency, asthma, atopy, and various malignancies-including prostate, breast, and renal cancers-where it often serves as a prognostic marker for metastasis and immunosuppressive tumor environments [3]. The R92H mutation (rs1805017) in the PLA2G7 gene is a non-synonymous polymorphism, which has been significantly associated with increased enzymatic activity and higher mass of the encoded Lp-PLA2 protein. Clinical studies consistently indicate that carriers of this variant face a heightened risk of coronary artery disease and clinical atherosclerosis, as the elevated enzyme activity promotes the release of pro-inflammatory mediators within vascular lesions [4].
The hPLA2G7-R92H is a mouse Pla2g7 gene humanized model carrying the R92H mutation constructed through gene-editing technology, in which the region from position p.F22 to partial intron 2 of the mouse Pla2g7 gene is replaced with the Mutant Human PLA2G7 CDS-rBG pA cassette. The murine signal peptide is retained. This model can be used for research on coronary artery disease (CAD) and clinical atherosclerosis, as well as for the development of PLA2G7-targeted therapeutics.
Reference
Stafforini DM. Plasma PAF-AH (PLA2G7): Biochemical Properties, Association with LDLs and HDLs, and Regulation of Expression. Enzymes. 2015;38:71-93.
Wang Y, Shi Y, Wu Z, Gao J, Wang J, Li L, Wan Y, Lang A M, Zhang J, Wang H, Hou Y. The Association of PLA2G7 Gene Polymorphisms with Serum Lp-PLA2 Activity and Lipid Profile in Han Chinese Patients with Coronary Heart Disease. Pharmgenomics Pers Med. 2024 Dec 21;17:563-572.
Akhmerova YN, Shpakova TA, Grammatikati KS, Mitrofanov SI, Kazakova PG, Mkrtchian AA, Zemsky PU, Pilipenko MN, Feliz NV, Frolova LV, Frolovskaya AA, Yudin VS, Keskinov AA, Kraevoy SA, Yudin SM, Skvortsova VI. Genetic Variants Associated with Bronchial Asthma Specific to the Population of the Russian Federation. Acta Naturae. 2023 Jan-Mar;15(1):31-41.
Luqman H, Mohammed N, Krishna Mohan I, Saibaba KSS, Sai Satish O, Bhaskar MV, Sreedevi NN, Khan SA. Unveiling the Synergy of Serum Lipoprotein-Associated Phospholipase A2 and PLA2G7 Gene Polymorphism (rs1805017) as Key Determinants of Coronary Artery Disease Risk and Severity: Implications for Early Intervention. Cureus. 2024 Nov 19;16(11):e74045.
Strain Strategy
The region from p.F22 to partial intron 2 of the mouse Pla2g7 gene was replaced with the Mutant Human PLA2G7 CDS-rBG pA cassette. The murine signal peptide was retained. The function of mouse 1700071M16Rik will be affected by deleting this KI region.
Figure 1. Gene editing strategy of hPLA2G7-R92H mice.
Application Area
Screening, development, and pre-clinical evaluation of PLA2G7-targeted drugs;
Research on the pathological mechanisms and treatment methods of coronary artery disease (CAD) and clinical atherosclerosis.
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.